Rx Partners
Executive Summary
Bristol-Myers Squibb and Lilly on March 18 join Roche, Parke-Davis, Searle and Upjohn as members of the informal group of companies in a program to send representatives to public forums to discuss pharmaceutical industry issues and to fax responses to attacks on the industry ("The Pink Sheet" March 15, T&G-2). Searle Chairman Sheldon Gilgore participated in a March 15 health care reform hearing in Des Moines featuring Hillary Rodham Clinton and appeared the following day on the network TV program CBS This Morning. Assisting Rx Partners under a $2 mil. contract is the Washington, D.C. consulting firm Powell Tate.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth